Synapse - Works

Results (2639)

Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma

Meeting Abstract

Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Blood (2020)

Fulltext@MSK | Save

RECIL 2017 criteria demonstrated similar prognostic value and detected a comparable treatment difference between obinutuzumab- and rituximab-chemotherapy compared with Cheson 2007 and Lugano 2014 criteria in patients with previously untreated advanced-stage follicular lymphoma

Meeting Abstract

Kostakoglu, L.; Davies, A.; Herold, M.; Hiddemann, W.; Marcus, R.; Trotman, J.; Knapp, A.; Mattiello, F.; Nielsen, T. G.; Sahin, D.; more...
Blood (2020)

Fulltext@MSK | Save

CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma

Meeting Abstract

Khodadoust, M. S.; Feldman, T. A.; Yoon, D. H.; Yannakou, C. K.; Radeski, D.; Kim, Y. H.; Mehta-Shah, N.; Khot, A.; Wilcox, R. A.; Kim, W. S.; more...
Blood (2020)

Fulltext@MSK | Save

Trial-in-progress: Frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma with less than 10% CD30 expression

Meeting Abstract

Jagadeesh, D.; Sims, R. B.; Horwitz, S. M.
Blood (2020)

Fulltext@MSK | Save

Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory lymphomas

Meeting Abstract

Imber, B. S.; Perales, M. A.; Flynn, J.; Ruiz, J. D.; Devlin, S.; Alarcon Tomas, A.; Hajj, C.; Batlevi, C. L.; Dahi, P. B.; Lin, R. J.; more...
Blood (2020)

Fulltext@MSK | Save

The ECHELON-2 trial: 5-year results of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in frontline treatment of patients with CD30-positive peripheral T-cell lymphoma

Meeting Abstract

Horwitz, S. M.; O'Connor, O. A.; Pro, B.; Illidge, T.; Iyer, S. P.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
Blood (2020)

Fulltext@MSK | Save

Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies

Meeting Abstract

Horwitz, S. M.; Foran, J. M.; Maris, M.; Sawas, A.; Okada, C.; Feldman, T. A.; Minden, M. D.; Sokol, L.; Mei, M.; Flinn, I. W.; more...
Blood (2020)

Fulltext@MSK | Save

CD5-positive marginal zone lymphoma: Clinical characteristics of the MSKCC Cohort, and comparison with the CD5-negative population

Meeting Abstract

Ghione, P.; Bantilan, K. S.; Joffe, E.; Lia Palomba, M.; Noy, A.; Matasar, M. J.; Caron, P.; Hamilton, A.; Hamlin, P. A.; Kumar, A.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical characteristics and follow-up post-surgery of women with BIA-ALCL operated at a single institution

Meeting Abstract

Ghione, P.; Vorstenbosch, J.; Cordeiro, P. G.; Arcila, M. E.; Moskowitz, A. J.; Owens, C.; Galasso, N.; Nelson, J. A.; Dogan, A.; McCarthy, C. M.; more...
Blood (2020)

Fulltext@MSK | Save

Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study

Meeting Abstract

Epstein-Peterson, Z. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Ho, C.; Jacob, A. P.; more...
Blood (2020)

Fulltext@MSK | Save